Intratumoral Injection of SD-101, an Immunostimulatory CpG, in Combination With BMS-986178 and Local Radiation in Low-Grade B-Cell Lymphomas
Phase of Trial: Phase I
Latest Information Update: 21 Jul 2018
At a glance
- Drugs BMS 986178 (Primary) ; SD 101 Dynavax (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 18 Apr 2018 Planned End Date changed from 1 Sep 2020 to 9 Oct 2020.
- 18 Apr 2018 Planned primary completion date changed from 1 Sep 2020 to 9 Oct 2020.
- 18 Apr 2018 Status changed from not yet recruiting to recruiting.